Test Menu

Solid Tumor Oncology

Anatomic Pathology

Morphology 
[SPC] Surgical Pathology Consultation  
[SPP] Surgical Pathology Professional  
Immunohistochemistry & Special Stains 
Refer to Printable IHC Test Menu for IHC Markers 

Molecular Oncology

[M COLON NGS] Colorectal Cancer NGS: BRAF, KRAS, NRAS 
[M EGFR] EGFR Mutation Analysis  
[M IDH1/2] IDH1/IDH2 Mutation Analysis 

Fluorescence in situ Hybridization (FISH)

Panels

[FP BURKITT] Burkitt / “Double Hit” Large Bcell Lymphoma Panel: CMYC, IGH::MYC, IGH::BCL2, BCL6

Probes 

[FP ALK] ALK 2p23 rearrangement  
[FP BCL1] IGH::BCL1 fusion t(11;14) 
[FP BCL2] IGH::BCL2 fusion t(14;18) 
[FP BCL6] BCL6 / 3q27 rearrangement  
[FP CMYC] C-MYC 8q24 rearrangement  
[FP EGFR] EGFR amplification 7p11.2  
[FP GLI] Oligodendroglioma, 1p-,19q- 
[FP HER2 HER2/neu amplification Breast Cancer
[FP HER2 GA] HER2/neu amplification Gastric Cancer
[FP IGH] IGH 14q32 rearrangement  
[FP IGH MYC] IGH::MYC fusion t(8;14)
[FP MALT] MALT1 18q21 rearrangement  

[FP IRF4] IRF4 6p25 rearrangement
[FP ROS1] ROS1 6q22.1 rearrangement 

Women's Health

STD and Infectious Disease

[CT] Chlamydia Trachomatis, Qualitative by Aptima COMBO® 2 TMA  
[HPV G] Human Papillomavirus Genotyping  
[HPV HR] Human Papillomavirus High Risk by Aptima HPV  
[HSV] Herpes Simplex Virus Type 1 and 2 Qualitative by PCR  
[NG] Neisseria Gonorrhoeae Qualitative by Aptima COMBO® 2 TMA  
[TV] Trichomonas Vaginalis by Aptima  

Other

Fluorescence in situ Hybridization (FISH)

[F URO] Bladder Cancer Panel (+3, +7, +17, 9p21-) 

Cytogenetics

[CYTO PB] Chromosome Analysis Peripheral Blood (Constitutional)  

Hematology Oncology

Anatomic Pathology

Morphology 
[BMPE] Bone Marrow Pathology Evaluation 
[SPC] Surgical Pathology Consultation  
[SPP] Surgical Pathology Professional  
Immunohistochemistry & Special Stains 
Refer to Printable IHC Menu for IHC Markers 

Cytogenetics

[CYTO BM] Chromosome Analysis Bone Marrow
[CYTO LN] Chromosome Analysis Lymphoma (Lymph Node)  
[CYTO LPB] Chromosome Analysis Leukemic Peripheral Blood  

Flow Cytometry

[FLOW] Flow Cytometry Leukemia / Myeloma / Lymphoma  
[FLOW TC] Flow Cytometry Technical Only  
[FLOW M] Flow Cytometry and Morphology  
[FLOW BAL] Bronchoalveolar Lavage: CD3, CD4, CD8, CD16, CD45, CD4:CD8 ratio 
[FLOW LAD] Leukocyte Adhesion Deficiency: CD11a, CD11b, CD11c, CD18 
[FLOW PNH] Paroxysmal Nocturnal Hemoglobinuria – High Sensitivity: FLAER, CD14, CD24, CD59 

Molecular Oncology

Next Generation Sequencing (NGS)

[M IgVH] IgVH Somatic Hypermutation  
[M MYD88] MYD88 p.L265P Mutation  
[M TP53] TP53 Mutation  
[M TCR] T-Cell Receptor Gamma Gene Rearrangement  

Fluorescence in situ Hybridization (FISH)
Hematology Panels

[F AML FRONTLINE] Acute Myeloid Leukemia Frontline Panel: -5/5q-, -7/7q-, t(8;21), CBFB, MLL(KMT2A)
[F AML SECONDARY] Acute Myeloid Leukemia Secondary Panel: MECOM, NUP98, t(6;9), t(9;22), TP53 (17p13)
[F BURKITT]
Burkitt / “Double Hit” Large Bcell Lymphoma Panel: CMYC, IGH::MYC, IGH::BCL2, BCL6
[F CLL] Chronic Lymphocytic Leukemia Panel: MYB (6q23), ATM (11q22.3), +12, DLEU1 (13q14.3), TP53(17p13) 

[F EOS] Eosinophilia panel: FIP1L1/CHIC2/PDGFRA, 4q12 rearrangement; PDGFRB, 5q32 rearrangement; FGFR1, 8p11.2 rearrangement 
[F MDS] Myelodysplasia Panel: -5/5q-, -7/7q-,  +8, 20q- 
[F MPD] Myeloproliferative Neoplasms Panel: +8, 13q-, 20q-, BCR::ABL1
[F MM] Plasma Cell Neoplasm Panel (performed on cells enriched for CD138+):  1p-, 1q+, +5, +9, IGH::CCND1, 13q-, +15, 17p- 

[F MM REF] Plasma Cell Neoplasm Reflex Panel (performed on cells enriched for CD138+): IGH::FGFR3, IGH::MAF

Hematology Probes

[F 4Q12] FIPIL1/PDGFRA 4q12 gene rearrangement

[F 7q] Deletion 7q22 (D7S796, D7S658)/7q31.2 (D7S486)

[F AML ETO] AML1::ETO t(8;21)

[F ATM] ATM/CEP11 deletion 11q22.3  

[F BCL1] IGH::BCL1 t(11;14)
[F BCL2] IGH::BCL2 t(14;18)
[F BCL3] BCL3 19q13.3 Rearrangement

[F BCL6] BCL6 3q27 rearrangement  
[F BCR ABL] BCR::ABL1 t(9;22)

[F CBFB] CBFB t(16;16), inv(16)  
[F CMYC] C-MYC 8q24 rearrangement  
[F D1314] Deletion 13q14.3  
[F D20] Deletion 20q12  
[F DEK::NUP214] DEK::NUP214 t(6;9)
[F EGR1] EGR1 5q deletion, monosomy 5  
[F ETV6::RUNX1] ETV6::RUNX1 t(12;21) gene fusion

[F FGFR1] FGFR1 8p11.2 Rearrangement
[F FGFR3] IGH::FGFR3 t(4;14) [F IGH] IGH 14q32 rearrangement  
[F IGH MAF] IGH::MAF t(14;16)
[F IGH MALT1] IGH/MALT1 t(14;18)
[F IGH MYC] IGH::MYC t(8;14)

[F IRF4] IRF4 6p25 rearrangement

[F MALT1] MALT1 18q21 rearrangement 

[F MECOM] MECOM 3q26 rearrangement

[F MLL] MLL (KMT2A) 11q23 Gene Rearrangement  
[F MYB] MYB 6q deletion  

[F NUP98] NUP98 11p15.5 rearrangement

[F P53] TP53 17p13 deletion 
[F PDGFRB] PDGFRB Gene Rearrangement  
[F PML RARA] PML::RARA t(15;17)

[F PRDM16] PRDM16 1p36 rearrangement

[F T12] Trisomy 12 

[F T21] Trisomy 21 

[F T8] Trisomy 8  

Our LIS Blue is a fast, easy-to-use, secure, and accessible laboratory information system developed using the latest web technology.

    Project Management

    Our project managers have strong scientific backgrounds and extensive experience in complex research-based clinical trials. They collaborate with our scientific operations, client services, and commercial operations teams to deliver high-quality, regulatory-compliant testing results on time at every project step.

    Key Features

    • Each study is assigned a dedicated and experienced project manager
    • Studies are typically set up within 6 to 8 weeks of contract signature
    • Project management software tools ensure timely deliveries
    • Onsite customer service teams efficiently resolve queries and deliver reports

    Benefits

    • Accelerated study setup time
    • Responsive communication with the scientific and operational team
    • Testing completed on time and within budget
    • Prompt reporting of critical study data

    Data Management

    The key to a successful clinical trial is accurate, clean, quality data. Our team of data managers provides you with data in customized formats exported to your data management teams from our in-house laboratory information system (LIS).

    Key Features

    • Access to dedicated and experienced data specialists upon contract award
    • Customized reports are agreed upon in study-specific data transfer agreement
    • In-house software development team for custom data solutions
    • Flexible data exports and data transfers

    Benefits

    • Real-time reports for your data and project teams to aid in patient management
    • Guaranteed data integrity and quality
    • Improved decision-making and enhanced patient safety
    • Timely access to accurate, clean data for intermediate or final database lock
    Genomic Solutions

    Genomic Solutions

    Genomic medicine, a vital tool in oncology and drug development by providing deeper, more personalized insights into each patient.
    Beyond informing drug target discovery, validation, and clinical development, it uncovers critical genetic markers that drive disease progression and influence individual responses to treatments. This empowers healthcare professionals to create more precise, tailored treatment plans, optimizing medical management based on each patient s unique genetic profile.

    Key features

    • Targeted NGS panels, including FDA-approved assays with companion diagnostic designations
    • Customized bioinformatics and reporting solutions
    • Robust assay designs to accommodate low-yielding biopsy material
    • Streamlined wet lab processes to meet screening window timelines

    Benefits

    • Identify variants along with key biomarker signatures
    • Save time and money by assessing multiple biomarkers in a single test
    • Enable targeted therapies with actionable, easy-to-interpret results
    • Assists in targeted patient stratification and recruitment
    • Accelerates the development of personalized medicine
    Digital Pathology

    Digital Pathology

    Digital pathology revolutionizes clinical trials by enhancing accessibility, cost-efficiency, compliance, and data management. MPLN’s comprehensive digital pathology services streamline clinical research, allowing for improved patient outcomes and operational efficiency.

    Features:

    • Seamless access to digital slides and slide retrieval enables instant access to digital slides.
    • Cost-effective digital slide management streamlines logistics by reducing the need for physical slide storage and transportation.
    • Digital storage ensures slides remain in perfect condition over time.

    Benefits:

    • Allows key opinion leaders (KOL) and remote client pathologists to be utilized
    • Digital slides can be easily shared, allowing for faster, more collaborative decisions, including obtaining second opinions.
    • Reduces the costs associated with physical storage and transport of slides, improving trial efficiency.
    • Simplifies regulatory processes, ensuring quicker and more accurate FDA submissions and audit readiness.
    • Prevents slide degradation or breakage, maintaining the quality of research data for the long term.
    • Enables broader patient recruitment by facilitating decentralized clinical trials for wider geographic participation, increasing patient recruitment and diversity.
    Global Logistics

    Global Logistics

    Effective global logistics are the cornerstone of effective specialty laboratory testing supporting global clinical trials. With precious patient samples such as biopsy and bone marrow aspirates, ensuring samples reach the lab on time and within stability is paramount.

    Key Features

    • Partnerships with global specialist couriers and large integrators to support global studies and specialty shipping requirements
    • Ambient, refrigerated, frozen, and liquid nitrogen storage and shipment services available
    • Real-time or batched shipments based on your clinical trial’s individual needs
    • Secure, high-volume, redundant data storage solutions for digital pathology images
    • Expert advice for effective sample collection, handling, and transport
    • Accurate tracking and inventory for all clinical trial specimens

    Benefits

    • Safe and effective transport of specimens worldwide
    • Standardized procedures to reduce pre-analytical variability and ensure valid results
    • Centralized and harmonized specialty pathology testing supported
    • Reduced costs and maximized budgets with fully managed logistics from one trusted source
    • Readily available inventories, manifests, and shipments for timely study closeouts
    Multiplex IHC

    IHC & Multiplex IHC

    Our advanced technology enables simultaneous visualization of single or multiple biomarkers within the same tissue section, delivering comprehensive insights and precise diagnostics. With unmatched expertise and cutting-edge technology, our team supports you in understanding complex tissue microenvironments, aiding patient stratification and treatment response prediction.

    Features:

    • Simultaneously visualize multiple biomarkers within the same tissue section for deeper insights.
    • Advanced analysis of tissue microenvironments to assist in patient stratification and treatment response prediction.
    • Custom assay design and flexible testing to meet your unique research or clinical trial needs.
    • Detailed data analysis and interpretation are provided by our expert team to ensure accurate results.

    Benefits:

    • Allows enhanced information from small biopsy samples. (I.e. NSCLC)
    • Gain comprehensive insights that lead to more precise diagnostics and better patient outcomes.
    • Enhanced ability to identify patient subgroups and better predict treatment responses with greater accuracy.
    • Whether in biomarker discovery or clinical trials, our advanced technology supports a range of applications, helping you unlock the full potential of your tissue samples.
    Cytogenetics FISH

    Cytogenetics & FISH

    We offer a comprehensive range of chromosome analysis and fluorescent in situ hybridization (FISH) testing with industry-leading turnaround times and global coverage. Our board-certified lab directors and experienced cytogenetic technologists ensure accurate, efficient, and competitively priced testing with the highest quality of service.

    Features:

    • Extensive FISH menu of over 40 loci and disease-specific panels detecting gene amplifications, deletions, translocations, and inversions.
    • Testing is available on bone marrow, blood, and FFPE tissue samples.
    • Specialized Offerings:
      • Plasma cell enrichment for plasma disorders
      • Stat turnaround for PML::RARA and acute myeloid leukemia
      • Bladder cancer urine analysis
      • Custom FISH assay development
    • Comprehensive chromosome analysis testing for oncology, infertility, recurrent pregnancy loss, and congenital disorders.
    • Global coverage of equivocal CAP/CLIA services supporting clinical trials

    Benefits:

    • Rapid, precise results critical for diagnosis and treatment.
    • Expert-driven testing with Board-certified experts ensures the highest accuracy.
    • Tailored assays and solutions to meet unique clinical needs.
    • Faster diagnostics support timely treatment decisions.